ARTICLE | Clinical News
Saphris asenapine regulatory update
March 30, 2015 7:00 AM UTC
FDA approved Saphris asenapine from Merck to treat manic or mixed episodes associated with bipolar I disorder in patients ages 10-17. Saphris is already approved in the U.S. to treat manic or mixed ep...